Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1428296 | 0.77 | ADRA2A (0.47) | HTTCA2 | |
| SCHEMBL2098949 | 0.77 | KMT2A (0.49) | — | |
| SCHEMBL4308231 | 0.76 | CCR1 (0.35) | — | |
| SCHEMBL3624625 | 0.74 | ADRA2A (0.46) | HTTCA2 | |
| SCHEMBL19650822 | 0.74 | HRH3 (0.44) | CA2 | |
| SCHEMBL514259 | 0.73 | ADRA2A (0.47) | — | |
| SCHEMBL2312226 | 0.73 | ADRA2A (0.47) | — | |
| SCHEMBL12986732 | 0.73 | RAB9A (0.40) | CA2 | |
| SCHEMBL24535941 | 0.72 | ESR1 (0.42) | HTT | |
| SCHEMBL29563534 | 0.72 | MBOAT4 (0.41) | HTTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794378-B2 | ANTIINFLAMMATORY AGENTS | AJINOMOTO CO., INC. (JP) | 2004-09-21 | — | — | US | disclosed |
| US-20020133005-A1 | Heterocyclic compounds and medical use thereof | AJINOMOTO CO., INC. (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1193255-A1 | HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF | Ajinomoto Co., Inc. (JP) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020133005-A1 | Heterocyclic compounds and medical use thereof | NFKBIA, CHUK, RELA | HTT 3717/4885CA2 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.